A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

Therapeutic tumor vaccines have become an important breakthrough in the treatment of various solid tumors including lung cancer. Dendritic cells (DCs)-based tumor vaccines targeting tumor-associated antigens (TAAs) play a key role in immunotherapy and immunoprevention. However, the weak immunogenici...

Full description

Bibliographic Details
Main Authors: Wuyi Zeng, Jiayi Pan, Zixuan Fang, Jiangtao Jia, Rong Zhang, Menghua He, Hanyu Zhong, Jiashan He, Xinyu Yang, Yi Shi, Bei Zhong, Jun Zeng, Bishi Fu, Maoping Huang, Hui Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
dendritic cells
MSLN
PD-L1
immunotherapy
therapeutic vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.925217/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.925217/full

Similar Items